SCHEMBL475037

SCHEMBL475037

O=C(O)n1cc2ccccc2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 2/20 0.43
ALDH1A1 P00352 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
MAPT P10636 1/20 0.42
MGAM O43451 2/20 0.41
CNR2 P34972 1/20 0.38
HPGD P15428 2/20 0.36
ALOX15 P16050 1/20 0.36
HSD17B10 Q99714 1/20 0.36
KDM4E B2RXH2 4/20 0.36
LMNA P02545 1/20 0.36
RAB9A P51151 3/20 0.35
NPC1 O15118 2/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
PRNP P04156 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
ESR2 Q92731 1/20 0.35
PARP1 P09874 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6337523 0.82 HDAC8 (0.39) HDAC8ALDH1A1SMN1; SMN2MAPTMGAM
SCHEMBL971386 0.82 SCN4A (0.40) HDAC8ALDH1A1SMN1; SMN2MAPTMGAM
SCHEMBL27769472 0.78 L3MBTL1 (0.44) HDAC8ALDH1A1SMN1; SMN2MAPTHPGD
SCHEMBL6027073 0.75 KMT2A (0.43) ALDH1A1SMN1; SMN2HSD17B10KDM4ERAB9A
Hydrochloric Acid SCHEMBL9124572 0.74 NOS1 (0.40) HDAC8MAPTKDM4ERAB9ANPC1
SCHEMBL25296039 0.74 HDAC8 (0.47) HDAC8ALDH1A1MAPTHPGDALOX15
SCHEMBL6891951 0.74 MEN1 (0.43) ALDH1A1MAPTHPGDKDM4ERAB9A
SCHEMBL27843276 0.73 KDM4E (0.38) HDAC8ALDH1A1SMN1; SMN2MAPTHPGD
SCHEMBL2066826 0.72 KDM4E (0.46) ALDH1A1SMN1; SMN2MAPTHPGDALOX15
SCHEMBL1774699 0.72 KDM4E (0.44) HDAC8ALDH1A1HPGDHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113439084-B Sesqui-carcinomycin analogue 奥克兰联合服务有限公司 2025-02-25 CN disclosed
CN-116265458-A Benzothiophene derivative, preparation method and application thereof 中国科学院上海药物研究所 2023-06-20 CN disclosed
EP-3917933-A1 DUOCARMYCIN ANALOGUES Auckland Uniservices Limited (NZ) 2021-12-08 EP disclosed
WO-2020157662-A1 DUOCARMYCIN ANALOGUES AUCKLAND UNISERVICES LIMITED (NZ) 2020-08-06 WO disclosed
CN-106170486-B Novel indazolecarboxamides, method for the production thereof, pharmaceutical preparations containing the same and use thereof for producing medicaments 拜耳医药股份有限公司 2019-01-15 CN disclosed
CN-105669668-A Pyridoindazole or benzopyridoindazole derivatives and synthesis method thereof 上海大学 2016-06-15 CN disclosed
CN-101880280-B Bicyclic pyrimidinones and uses thereof SHANGHAI INST ORGANIC CHEM 2014-07-16 CN disclosed
CN-101627019-B Bicyclic pyrimidinones and uses thereof AVEXA LTD 2013-07-10 CN disclosed
EP-2411001-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN Merck Sharp & Dohme Corp. (US) 2012-02-01 EP disclosed
US-8048537-B2 Cyclometalated transition metal complex and organic light emitting device using the same SAMSUNG MOBILE DISPLAY CO., LTD. (KR) 2011-11-01 US disclosed
WO-2006047277-A2 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed
CN-1753671-A 1,3-substitued cycloalkyl derivatives having acidic, mostly heterocyclic groups, processes for their preparation and their use as pharmaceuticals SANNOFFE AVENTIS PHARMA GMBH (DE) 2006-03-29 CN disclosed
EP-1381366-A4 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2005-02-16 EP disclosed
US-6825201-B2 ANTIVIRAL ACTIVITY; TREATMENT OF HIV AND AIDS BRISTOL-MYERS SQUIBB COMPANY 2004-11-30 US disclosed
CN-1520295-A Indole, azaindole and related heterocyclic amidopiperazine derivatives ����˹�ж�-����˹˹������˾ 2004-08-11 CN disclosed
EP-1381366-A2 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-21 EP disclosed
US-20030096825-A1 Indole, azaindole and related heterocyclic amidopiperazine derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2003-05-22 US disclosed
EP-1268486-A2 FUSED HETEROCYCLIC DERIVATIVES, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 2003-01-02 EP disclosed
WO-2002085301-A2 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2002-10-31 WO disclosed
WO-2001074823-A2 FUSED HETEROCYCLIC DERIVATIVES, THEIR PRODUCTION AND USE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096825-A1 Indole, azaindole and related heterocyclic amidopiperazine derivatives IDO1, IDO2, INMT HDAC8 1007/4885ALDH1A1 3050/4885SMN1; SMN2 4791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.